Based on the limited research available, regular marijuana use does not appear to significantly reduce ketamine’s antidepressant effects. One study comparing depression outcomes in cannabis users and non-users found virtually identical improvement after ketamine treatment. But the picture is more complicated than that headline suggests, because THC and CBD interact with ketamine through different mechanisms, side effects may compound in ways that matter for certain patients, and the research base is still thin enough that clinicians vary widely in their recommendations.
What the Depression Outcome Data Actually Shows
The most directly relevant evidence comes from a study that compared depression scores in people receiving ketamine who were active cannabis users versus those who were not. Both groups improved by a nearly identical margin: non-users saw about a 4.5-point drop on a standard depression scale, while cannabis users saw about a 4.3-point drop. At no point during the study was there a meaningful difference between the two groups.1medRxiv. Effects of cannabis use on antidepressant treatment response to repetitive transcranial magnetic stimulation and ketamine
That finding is reassuring if your primary concern is whether smoking or consuming cannabis will cancel out ketamine’s mood-lifting benefits. It did not, at least in this cohort. But a single study with around 120 participants leaves a lot of room for uncertainty, and it does not tell you anything about differences in side effects, dissociative experiences, or longer-term outcomes beyond the study window. The researchers measured depression scores, not the full spectrum of what a patient might care about when combining these two substances.
How Cannabinoids and Ketamine Overlap in the Brain
Both marijuana and ketamine influence the same broad signaling system in the brain, which is part of why their interaction matters at all. Ketamine works primarily by blocking NMDA receptors, a type of glutamate receptor involved in mood regulation and neural plasticity. THC, the psychoactive compound in marijuana, activates CB1 receptors, which are physically linked to those same NMDA receptors. When CB1 receptors get activated, they can dampen NMDA receptor activity.2PubMed Central. Endocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunction Since ketamine is also reducing NMDA activity from the other direction, combining the two could theoretically create a situation where NMDA function drops lower than intended.
Both substances also reduce the activity of a type of inhibitory brain cell that helps keep neural firing coordinated. When those cells are suppressed from two directions at once, neural signaling can become more disorganized, which could amplify dissociative or perceptual disturbances.3European Journal of Neuroscience. Cannabinoid-glutamate interactions and neural oscillations: implications for psychosis In practical terms, this means the two drugs are not acting on completely separate systems. They are tugging on overlapping circuits, which creates both the potential for unwanted effects and, intriguingly, the possibility that certain cannabinoids could modulate ketamine’s side-effect profile in useful ways.
THC and CBD Tell Very Different Stories
One of the biggest misconceptions about this topic is treating “marijuana” as a single substance. Cannabis contains dozens of active compounds, and the two most prominent, THC and CBD, interact with ketamine in almost opposite ways. This distinction matters enormously if you are trying to figure out whether your particular cannabis use is likely to affect your ketamine treatment.
CBD has shown surprisingly promising interactions with ketamine in laboratory studies. In animal research, pretreatment with CBD preserved ketamine’s antidepressant effect while preventing the hyperactivity that typically accompanies ketamine administration. Both compounds appeared to work through a shared downstream mechanism involving a specific type of glutamate receptor (AMPA), which is believed to be central to ketamine’s rapid mood-lifting action.4PubMed. Co-administration of cannabidiol and ketamine induces antidepressant-like effects devoid of hyperlocomotor side-effects The researchers concluded that combining the two could be a promising strategy for keeping the therapeutic benefit while reducing unwanted effects.
In a small human study, CBD produced a more complex pattern when given alongside ketamine to healthy volunteers. It amplified some of ketamine’s activating effects but showed a trend toward reducing feelings of depersonalization, the unsettling sense of detachment from yourself that some people find distressing during ketamine sessions.5PubMed. The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects That trend did not reach statistical significance, but it is consistent with what the animal research suggested: CBD and ketamine have a complicated but not necessarily antagonistic relationship.
THC is a different matter. As the compound that binds most strongly to CB1 receptors, THC is the one most likely to pile onto ketamine’s NMDA-dampening effects and amplify dissociation or psychotomimetic experiences. Research measuring the psychoactive profiles of cannabis and ketamine separately has found that both reliably produce increases in perceptual disturbances and altered states.6Schizophrenia Research. The psychotomimetic states inventory (PSI): measuring psychotic-type experiences from ketamine and cannabis When you combine two substances that each independently push perception in similar directions, the risk of unpleasant or overwhelming experiences goes up, even if neither one alone would have caused a problem.
Why Side Effects Matter Even If Efficacy Is Preserved
The outcome study showing equivalent antidepressant improvement tells part of the story, but for many patients the question is not just “will ketamine still work?” but “will I feel safe and functional during and after treatment?” Ketamine sessions can produce dissociation, nausea, elevated blood pressure, and perceptual disturbances. These effects are dose-dependent and typically resolve within a couple of hours, but they can be anxiety-provoking, and anything that intensifies them could make the treatment harder to tolerate or cause a patient to discontinue.
This is where the mechanistic overlap between THC and ketamine becomes practically relevant. If you arrive at a ketamine session with THC still active in your system, you are more likely to experience stronger dissociative effects, not because ketamine stopped working but because both substances are pushing in the same direction on the same neural circuits. For someone who is already anxious about the ketamine experience, that amplification could be the difference between a tolerable session and one that feels destabilizing.
CBD-dominant products, on the other hand, might theoretically smooth some of those rough edges based on the early evidence. But “theoretically” and “based on animal studies” are doing a lot of heavy lifting in that sentence. No clinical trial has tested CBD as a deliberate adjunct to therapeutic ketamine infusions in depressed patients. The human data comes from a small study in healthy volunteers, not people being treated for depression, and the doses and timing may not translate to real-world cannabis use.
What Clinicians Typically Tell Patients
Because the evidence is thin and almost entirely preclinical or observational, recommendations from ketamine providers vary. Some clinics ask patients to abstain from all cannabis for 24 to 48 hours before a session, reasoning that even a small increase in dissociative side effects is worth avoiding. Others focus specifically on THC, asking patients to avoid it on the day of treatment while being less concerned about CBD. And some clinics do not screen for cannabis at all, particularly if the patient has a longstanding pattern of use and is not reporting side-effect issues.
There is no published clinical guideline from a major medical society specifically addressing marijuana use during ketamine treatment for depression. The recommendations you encounter are based on clinical judgment informed by the pharmacology rather than on randomized trial data showing harm. That is a real gap. It means your clinician’s advice will depend heavily on their personal practice style, their comfort with uncertainty, and how they weigh theoretical risk against the practical reality that many of their patients use cannabis.
If you use cannabis regularly and are starting ketamine treatment, the most reasonable approach is to be transparent with your provider about what you use, how often, and whether your products are THC-dominant, CBD-dominant, or mixed. That gives them the information they need to adjust your treatment plan, monitor you more closely during sessions if warranted, and help you distinguish between ketamine effects and cannabis-related effects if something unexpected happens.
Chronic Users Versus Occasional Users
Another variable that the current research barely addresses is tolerance. Daily cannabis users have a substantially different neurochemical landscape than someone who uses it once a month. Chronic THC exposure downregulates CB1 receptors, meaning the same dose of THC produces less effect over time. In theory, a daily user’s dampened CB1 system might interact with ketamine differently than an occasional user’s fully sensitized one. The outcome study that found no difference between cannabis users and non-users did not break down results by frequency or intensity of use, so we cannot yet say whether heavy daily use carries a different risk profile than occasional use.1medRxiv. Effects of cannabis use on antidepressant treatment response to repetitive transcranial magnetic stimulation and ketamine
Timing also matters in a way that the available data does not resolve. THC consumed hours before a ketamine infusion is pharmacologically different from THC consumed the night before. Acute intoxication with THC during a ketamine session is the scenario most likely to produce compounded dissociative effects, while residual THC metabolites in a chronic user’s system may have little practical impact on the treatment experience. Until studies specifically examine dosing windows, these distinctions remain educated guesses based on what we know about each drug’s pharmacokinetics individually.
Ketamine as a Treatment for Cannabis Use Disorder
An interesting twist in this story is that ketamine is being studied not just alongside cannabis but as a potential treatment for people who want to stop using it. A proof-of-concept study found that ketamine infusions combined with behavioral therapy significantly reduced how often participants used cannabis, with the drop persisting through the end of the study. Participants also reported greater confidence in their ability to stay away from cannabis in situations that would normally trigger use.7PubMed. Ketamine-facilitated behavioral treatment for cannabis use disorder: A proof of concept study
A broader systematic review looking at ketamine’s role across various substance use disorders confirmed that finding, noting that ketamine reduced weekly cannabis use and boosted abstinence confidence in people with cannabis use disorder.8Journal of Substance Use and Addiction Treatment. Role of ketamine in the treatment of substance use disorders: A systematic review This is still early-stage research, not standard practice, but it highlights that the relationship between ketamine and cannabis is not purely one of interference. For some people, ketamine may actually help recalibrate the motivation circuits that drive problematic cannabis use.
This research does create a somewhat paradoxical situation for patients who are using ketamine for depression and also using cannabis. If ketamine can reduce cannabis cravings as a side benefit, some patients may find their cannabis use naturally declining during treatment. Others may be using cannabis specifically to manage anxiety or insomnia between ketamine sessions, in which case the relationship between the two substances is more about self-management than interference.
CBD and Ketamine in Early Brain Development Research
Beyond the depression context, researchers are exploring whether CBD and ketamine have complementary effects in other areas. In one animal study focused on how early drug exposure affects later behavior, both CBD and ketamine given in adulthood reduced voluntary alcohol consumption in rats that had been exposed to alcohol during adolescence. CBD was effective in both males and females, while ketamine showed a clear benefit only in females.9PubMed Central. Cannabidiol or ketamine for preventing the impact of adolescent early drug initiation on voluntary ethanol consumption in adulthood
This is not directly about marijuana interfering with ketamine treatment, but it reinforces a broader theme in the literature: CBD and ketamine appear to share some downstream neuroplasticity mechanisms that can work in complementary rather than conflicting ways. THC, by contrast, tends to activate receptor pathways that either parallel or amplify ketamine’s more disruptive effects. The recurring pattern across multiple research areas is that lumping all cannabis compounds together misses the point. The specific compound, its dose, and its timing relative to ketamine all change the nature of the interaction.
What the Research Still Cannot Tell You
The honest state of the science here is frustrating. We have one clinical study on depression outcomes that found no interference, a handful of mechanistic studies suggesting the interaction is pharmacologically real but complex, and a few animal studies hinting that CBD may actually improve ketamine’s side-effect profile. What we do not have is a single large randomized trial that specifically set out to measure whether cannabis use changes ketamine’s antidepressant efficacy, its side-effect burden, or its durability over multiple treatment sessions.
We also lack data on edibles versus smoking, high-THC strains versus balanced strains, or the effects of synthetic cannabinoids that some people use. The research treats cannabis use as a binary: you use it or you do not. Real-world cannabis consumption is vastly more varied than that, and until studies account for the type, potency, route, and timing of cannabis use relative to ketamine sessions, blanket recommendations in either direction are built on thin evidence. If your provider tells you cannabis use is fine, they are probably not wrong based on the depression outcome data. If another provider tells you to avoid it, they are also not wrong based on the pharmacological overlap. Both positions are defensible, which is another way of saying the research has not yet caught up to the question patients are actually asking.